Fluoxetine's effect on anger-related emotional responses in young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Healthy volunteers aged 18–24 are given either 20 mg fluoxetine or a matching placebo each day for seven days and then attend the university for questionnaire and behavioural task assessments. Tasks probe responses to anger-related stimuli (words, faces, autobiographical recall) and include frustration-inducing paradigms such as frustrative non-reward and threat tasks. During some tasks researchers record physiological measures including heart rate variability and facial expressions to capture bodily markers of emotional response. The trial compares behavioural and physiological responses between the fluoxetine and placebo groups to see if short-term dosing alters anger processing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Be aged 18-24 years (inclusive)
* Be resident in the UK for the duration of the study
* Have normal or corrected to normal vision
* Participant is willing and able to give informed consent for participation in the research
* Sufficiently fluent English to understand and complete the study

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

Psychiatric History:

* Current or past diagnosis of any psychiatric disorder, as determined by the Structured Clinical Interview for the DSM-5 (SCID-5) and self-report. This includes, but is not limited to, depression, anxiety disorders, alcohol or drug dependency, personality disorders, suicidal ideation, and other psychiatric conditions;
* First degree relative with a diagnosis of mania;

Lifestyle:

* Heavy smoker or vaper (\> 10 cigarettes per day, or \>2 mL e-liquid, or \>15mg/day from a nicotine patch);
* Heavy use of caffeine (drink \> 4 of 250ml cups/cans of coffee or energy drinks per day);
* Heavy drinker (drink \>14 standard alcoholic drinks per week);
* Current or recent use (in the last 3 months) of any psychoactive substance according to self-report and a urine drug test screening for recent use of 10 common recreational substances;

Physical Health:

* Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medical advisor;
* Known contraindication to fluoxetine, such as hypersensitivity to fluoxetine or any component in its formulation;
* Pregnancy, as determined by a urine pregnancy test or plans to become pregnant within the next 3 months;
* Breastfeeding;
* Not able to consume gelatine;

Medical History:

* Past or ongoing health issue which, in the opinion of the study medical advisor, may interfere with the safety of the participant or the scientific integrity of the study, including but not limited to: seizures or epilepsy, heart rhythm problem, renal disease, hepatic disease, glaucoma, diabetes, bleeding disorders or clotting conditions (e.g., haemophilia, thrombocytopenia);
* Diagnosis of a significant neurological condition (e.g., epilepsy, multiple sclerosis, traumatic brain injury).
* Diagnosis of a neurodevelopmental condition, such as autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD);
* Current or recent use of medication that might interfere or interact with the effects of fluoxetine, in the opinion of the study medical advisor, including but not limited to: monoamine oxidase inhibitors (MAOIs), medications affecting serotonin levels (e.g., tramadol, triptans, St. John's Wort), anticoagulants or blood thinners (e.g., warfarin), anti-inflammatory medications (e.g., aspirin, ibuprofen), or medications known to affect heart rhythm;

Prior Study Participation:

* Participation in any other psychological or medical experiment involving taking any kind of drug/medication/vaccine, within the last 3 months;
* Participation in any other study involving the current or similar tasks, within the last 6 months;

Others

•Any other significant finding which may arise during the screening process and which, in the opinion of the Principal Investigator/medical advisor, may influence the scientific integrity of the study, or the participant's ability to participate in the study.

Where it's running

• Department of Psychiatry, University of Oxford
  Oxford, Oxfordshire, United Kingdom Recruiting

Study contacts

• Study coordinator: Catherine Harmer, PhD
• Email: catherine.harmer@psych.ox.ac.uk
• Phone: +441865 618326

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Step-by-step care plan to improve treatment for moderate depression in general practice

  It tests whether a structured step-by-step care plan used by general practitioners works better than usual GP care or psychologist-led behavioral therapy for adults 18–65 with moderate depression.

  Recruiting Aalborg University Hospital · Aalborg · NCT07263321

• Heated yoga, sauna, or a mindfulness app for depression

  This project will test whether heated yoga, sauna sessions, or a mindfulness app reduce symptoms in adults with at least moderate depression.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07082998

• CYB003, a deuterated psilocin, for adults with major depressive disorder

  This trial will test whether adding CYB003 to a current antidepressant helps reduce symptoms in adults with major depressive disorder who have not responded well to their medication.

  Recruiting at 51 sites Phase 3 Cybin IRL Limited · Birmingham, Alabama and 78 other locations · NCT06793397

• Personalized brain stimulation for long-term symptoms after concussion

  This study will try personalized, noninvasive brain stimulation (TMS) to reduce dizziness, headaches, memory problems, and other lasting symptoms in adults aged 18–65 after a concussion.

  Recruiting Phase 2 University of California, Los Angeles · Westwood, Los Angeles, California · NCT06073886

• Smartphone-supported single-session psychotherapy for postpartum depression

  A single online therapy session plus four weeks of app-based support is being tested to see if it reduces depressive symptoms in postpartum women compared with a waitlist.

  Recruiting University of Sao Paulo · São Paulo, São Paulo · NCT07925762

• Understanding how the orbitofrontal cortex guides approach vs. avoidance in depression

  This study tests how different parts of the orbitofrontal cortex influence whether people pursue rewards or risk loss, and whether this pattern is altered in Major Depressive Disorder.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07896343

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.